Abstract
Neurodegenerative diseases occur when neurons in the central and/or peripheral nervous systems lose function over time and ultimately die. They are characterized by common cellular and molecular mechanisms including protein aggregation and inclusion body formation, categorising each type of disease. Therefore, the definitive diagnosis is at post-mortem, based on pathology. However, the development of various molecular imaging techniques has enabled pathological changes to be inferred in vivo. Decreased myocardial 123I-mIBG uptake has been reported in some patients with neurodegenerative diseases. This review is aimed to synthesise the basis, methodology and clinical role of myocardial 123I-mIBG imaging in the diagnosis of certain neurodegenerative diseases, focusing on its utility to differentiate some neurodegenerative Parkinsonisms between them, and to differentiate dementia with Lewy bodies from Alzheimer’s disease and other dementias.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
